Back

EMPEROR-Preserved: effect of empagliflozin on cardiovascular death and heart failure hospitalisations in patients with heart failure with a preserved ejection fraction, with and without diabetes

27 August 2021 (17:25 - 17:37)
Organised by:
Congress Presentation Part of: Hot Line - EMPEROR-Preserved / EMPEROR-Pooled Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Professor Stefan Anker

Charite University Hospital, Berlin (Germany)

4 More presentations in this session

Presentation thumbnail
EMPEROR-Preserved - Discussant review.
Professor F. Ruschitzka (Zurich, CH)
Video
Presentation thumbnail
EMPEROR-Pooled: effect of empagliflozin on serious adverse renal outcomes in chronic heart failure – a prospective alpha-protected, Individual patient-level pooled analysis
Professor M. Packer (Dallas, US)
Slides Video
Presentation thumbnail
EMPEROR-Pooled - Discussant review.
Professor R. De Boer (Rotterdam, NL)
Slides Video
Presentation thumbnail
EMPEROR-Preserved / EMPEROR-Pooled - Panel discussion.

Access the full session

Session thumbnail
Hot Line - EMPEROR-Preserved / EMPEROR-Pooled
Video

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 17:25 CET
You may be interested in
thumbnail
Congress Presentation
DELIVER - Dapagliflozin in Heart Failure with Mildly Reduced and Preserved Ejection Fraction.
thumbnail
Congress Session
Hot Line - EMPEROR-Preserved / EMPEROR-Pooled

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources